Zobrazeno 1 - 10
of 19 949
pro vyhledávání: '"Antivirals"'
Autor:
Fernando Chacón, Luis Morano, Jordi Navarro, Rafael Granados, Josep Mª Llibre, Pablo Ryan, Teresa Aldámiz-Echevarria, Luz Martín Carbonero, Marc Puigvehí, Imma Clotet-Codina, Nuria Sanchez-Vega, Enrique Vacas, Oscar Rincón, Juan Berenguer, Javier Crespo, Carlos Roncero
Publikováno v:
BMC Public Health, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Hepatitis C virus (HCV) reinfection following successful treatment threatens the achievement of HCV elimination. The primary aim of this study is to assess reinfection rate three years after sustained virologic response (SVR) in p
Externí odkaz:
https://doaj.org/article/8b8343c884894a8090d0c57af0718ffc
Autor:
Rongyuan Gao, Philippe Noriel Q. Pascua, Anton Chesnokov, Ha T. Nguyen, Timothy M. Uyeki, Vasiliy P. Mishin, Natosha Zanders, Dan Cui, Yunho Jang, Joyce Jones, Juan De La Cruz, Han Di, Charles Todd Davis, Larisa V. Gubareva
Publikováno v:
Emerging Infectious Diseases, Vol 30, Iss 11, Pp 2303-2312 (2024)
Since 2013, a total of 167 human infections with swine-origin (variant) influenza A viruses of A(H1N1)v, A(H1N2)v, and A(H3N2)v subtypes have been reported in the United States. Analysis of 147 genome sequences revealed that nearly all had S31N subst
Externí odkaz:
https://doaj.org/article/f305c0258a0e4d90955297bc68b1106d
Autor:
Johannes Bernhard, Michael Schwarz, Lorenz Balcar, Benedikt Hofer, Nina Dominik, Robert Strassl, Stephan Aberle, Petra Munda, Mattias Mandorfer, Michael Trauner, Thomas Reiberger, Mathias Jachs
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract Current guidelines recommend reflex testing for hepatitis D virus (HDV) coinfection in hepatitis B surface antigen (HBsAg)-positive patients over risk-factor based screening. We aimed to evaluate the feasibility and diagnostic yield of refle
Externí odkaz:
https://doaj.org/article/5ff8d5f088d54ab1a6e5e26d8a9bafb3
Autor:
Dorota Zarębska-Michaluk, Michał Brzdęk, Olga Tronina, Justyna Janocha-Litwin, Marek Sitko, Anna Piekarska, Jakub Klapaczyński, Anna Parfieniuk-Kowerda, Barbara Sobala-Szczygieł, Magdalena Tudrujek-Zdunek, Łukasz Laurans, Robert Flisiak
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-11 (2024)
Abstract Background Eliminating hepatitis C virus (HCV) infections is a goal set by the World Health Organization. This has become possible with the introduction of highly effective and safe direct-acting antivirals (DAA) but limitations remain due t
Externí odkaz:
https://doaj.org/article/2b3b1b2c568045c6bb363b56381eaabf
Publikováno v:
Infection and Drug Resistance, Vol Volume 17, Pp 3967-3978 (2024)
Ximiao Yu,1,* Ruiqi Luo,2,* Guijuan Xie,2 Jiali Ji,3,4 Jiehong Wang,1 Xiyue Li,3 Xiaojun Qian,2 Xun Wang1,2,5 1Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu Province, People’s Republic of China; 2Department of Pulmonary and Cr
Externí odkaz:
https://doaj.org/article/d8e82d493dc54688b5b23018834f80fe
Autor:
Takeshi Tomida, Takeshi Kimura, Kazuhiro Yamamoto, Atsushi Uda, Yuki Matsumoto, Naoki Tamura, Masashi Iida, Akiko Tanifuji, Kumiko Matsumoto, Naomi Mizuta, Kei Ebisawa, Goh Ohji, Tomohiro Omura, Kentaro Iwata, Ikuko Yano
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 10, Iss 1, Pp 1-12 (2024)
Abstract Purpose While nirmatrelvir/ritonavir (NMV-r) has been positioned as a first-line treatment for mild to moderate COVID-19, it has multiple and significant drug-drug interactions (DDIs). The use of NMV-r in Japan has been limited compared to t
Externí odkaz:
https://doaj.org/article/96e1fb92be494ee0a05d38ad27641599
Publikováno v:
Gastroenterology Insights, Vol 15, Iss 3, Pp 676-707 (2024)
According to the World Health Organization (WHO), the incidence of HCV remains high (around 1.5 million new patients every year), and 80% of patients with acute infection will progress to chronic hepatitis and develop cirrhosis and even liver cancer.
Externí odkaz:
https://doaj.org/article/667a0f65e1b047bda79b5108010b5085
Autor:
Anna S. F. Lok
Publikováno v:
Gut and Liver, Vol 18, Iss 4, Pp 593-601 (2024)
Current treatment of chronic hepatitis B virus (HBV) infection, pegylated interferon-α (pegIFN-α) and nucleos(t)ide analogue (NA), can suppress HBV replication, reverse liver inflammation and fibrosis, and decrease risks of cirrhosis and hepatocell
Externí odkaz:
https://doaj.org/article/cf9f566970f640ac8ddce25d7e3a5556
Autor:
Walaa Abdelhamed, Mohamed El-Kassas
Publikováno v:
Egyptian Liver Journal, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Hepatitis B virus (HBV) infection is a significant global public health threat with variable geographical distribution. Chronic infection with HBV could be complicated by chronic hepatitis state, progression to liver cirrhosis, and the devel
Externí odkaz:
https://doaj.org/article/403d3be0229246f9bcc01e314670dbee
Publikováno v:
Антибиотики и Химиотерапия, Vol 69, Iss 3-4, Pp 14-20 (2024)
Background. Annual studies of West Nile virus (WNV) circulating in endemic areas are necessary to characterize its properties and track them over time. Given the lack of specific antiviral therapy for West Nile fever (WNF), it is of interest to study
Externí odkaz:
https://doaj.org/article/248f4ef1b3ff4b1195f1811e4a9249d1